Roche lays out bold obesity strategy with CT-388 at the center

Swiss pharma major Roche (ROG: SIX) has unveiled its long-awaited plan to crack the booming obesity market, targeting a top-three position before 2030.

At its Pharma Day presentation in London, pharma head Teresa Graham said the company would rely on a mix of late-stage and early assets, alongside its global commercial footprint.

Roche’s centerpiece is CT-388, a dual GLP-1/GIP receptor agonist gained via the $2.7 billion acquisition of Carmot Therapeutics. The candidate showed nearly 19% placebo-adjusted weight loss at 24 weeks in a Phase I trial and is now heading for pivotal testing. A Phase III study is set to begin in the first half of next year, with programs in chronic weight management planned for 2026.